ClinicalTrials.gg
CompletedNCT03187678Updated Jun 29, 2025Results posted

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

A Phase 3 interventional study of i.v. selexipag and oral selexipag (Uptravi) in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 8 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.

Enrollment
9th of 12
20 · median 67
Started
2017
with 1 other
Phase 3
6 of 12
1 open now
Registered
6th of 12
by date
Lead sponsor
9 of 12
Actelion

Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one is the 9th largest by enrollment, is one of 2 that started in 2017, is one of 6 in phase 3, and was the 6th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About selexipag

selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing selexipag in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The development of selexipag for intravenous administration will be useful to avoid treatment interruptions in patients with pulmonary arterial hypertension (PAH) already treated with selexipag administered orally as tablets (Uptravi®). The target population for intravenous selexipag includes those PAH patients who are hospitalized and are unable to swallow tablets of Uptravi.

The primary objective of this study is to assess whether it is safe for patients with PAH to temporarily change from selexipag tablets (Uptravi®) to selexipag given directly into a vein (intravenous selexipag), and then switching back to the initial oral dose of selexipag.

Read the detailed description

After screening (Visit 1), each subject will participate in the following consecutive treatment periods: Period 1(treatment with oral selexipag at Visit 2/Day 1), Period 2 (treatment with intravenous selexipag at Visit 2/ Day 2 and Day 3), Period 3 (treatment with oral selexipag starting in the evening of Visit 2/Day 3 and ending 7 to 11 days later at Visit 3). Then a safety follow-up period is planned up to end of study visit (EOS), which occurs between Day 33 and Day 40.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • switch
  • intravenous
  • selexipag
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form prior to any study-mandated procedure.
  • Male and female subjects aged from 18 to 75 years (inclusive),
  • Subjects with stable pulmonary arterial hypertension (PAH) defined as WHO Functional Class I-III at Visit 1 and Visit 2, and no change (i.e., introduction or dose change) in PAH-specific medication (i.e., ERA, PDE-5 inhibitor or sGC stimulator) and diuretics in the last 28 days prior to Visit 2.
  • Subjects currently treated with Uptravi® at a stable dose (i.e. unchanged dose) for at least 28 days before Visit 2.
  • Women of must have a negative pregnancy test at Visit 1 (screening) and Visit 2.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, planning to become pregnant or lactating.
  • Known and documented moderate or severe hepatic impairment.
  • Subjects having received gemfibrozil at any time since initiation of Uptravi®.
  • Treatment with any prostacyclin and prostacyclin analogs within 28 days prior to Visit 1.
  • SBP \< 90 mmHg at Visit 1 or at Visit 2.
  • Known or suspected uncontrolled hyperthyroidism.
  • Severe renal failure and ongoing or planned dialysis.
  • Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results.
  • Known concomitant life-threatening disease with a \< 12 months.
  • Treatment with another treatment within 3 months of Visit 1.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Selexipag

    Subjects with stable pulmonary arterial hypertension (PAH) and currently treated with a stable oral dose of Uptravi will be switched to i.v. selexipag from Day 2 to Day 3 (2 infusions on Day 2 and 1 infusion on Day 3). Otherwise, they will continue with their current oral selexipag treatment throughout the study.

    Drug: i.v. selexipag · Drug: oral selexipag (Uptravi)

Interventions

  • Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.

    Also known as: ACT-293987

  • Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information

    Also known as: ACT-293987

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One Adverse Event (AE)

    AE is any untoward medical event that occurs in a participant during the course of the study whether or not considered by the investigator as related to the study treatment.

    Time frame: From Day 1 to Day 37

  2. Number of Participants With Prostacyclin-associated Adverse Events

    Prostacyclin-associated AE include headache, diarrhea, nausea, vomiting, jaw pain, myalgia, pain in the extremity, flushing and arthralgia.

    Time frame: From Day 1 to Day 37

  3. Number of Participants With Adverse Event Related to Injection Site Reactions

    This is the number of participants with at least one clinically significant reaction at the injection site (e.g., erythema/redness, tenderness, swelling, induration, hemorrhage at the injection site) occurring on the days of intravenous (iv) selexipag injection.

    Time frame: From Day 2 to Day 3

  4. Number of Participants With Prostacyclin-associated AEs Leading to Study Treatment Discontinuation

    This is the number of subjects who discontinued the i.v. selexipag treatment due to prostacyclin-associated adverse events (headache, diarrhea, nausea, vomiting, jaw pain, myalgia, pain in the extremity, flushing and arthralgia).

    Time frame: From Day 2 to Day 3

  5. Number of Participants With PAH-related Adverse Events

    This is the number of participants with at least one AE considered to be related to pulmonary arterial hypertension during the course of the study.

    Time frame: From Day 1 to Day 37

07

Results

Posted May 21, 2019

Participant flow

Twenty-two patients treated with Uptravi for pulmonary arterial hypertension (PAH) were screened; 20 of them were enrolled in the study.

Period 1 (Oral Selexipag)
Participant flow — Period 1 (Oral Selexipag)
MilestoneSelexipag
Started20
Completed20
Not completed0
Period 2 (Intravenous Selexipag)
Participant flow — Period 2 (Intravenous Selexipag)
MilestoneSelexipag
Started20
Completed20
Not completed0
Period 3 (Oral Selexipag)
Participant flow — Period 3 (Oral Selexipag)
MilestoneSelexipag
Started20
Completed20
Not completed0

Outcome measures

PrimaryNumber of Participants With at Least One Adverse Event (AE)

AE is any untoward medical event that occurs in a participant during the course of the study whether or not considered by the investigator as related to the study treatment.

Time frame:
From Day 1 to Day 37
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event (AE)
ParticipantsSelexipag
Number of Participants With at Least One Adverse Event (AE)15
PrimaryNumber of Participants With Prostacyclin-associated Adverse Events

Prostacyclin-associated AE include headache, diarrhea, nausea, vomiting, jaw pain, myalgia, pain in the extremity, flushing and arthralgia.

Time frame:
From Day 1 to Day 37
Reported as:
Count of participants · Participants
Number of Participants With Prostacyclin-associated Adverse Events
ParticipantsSelexipag
Number of Participants With Prostacyclin-associated Adverse Events7
PrimaryNumber of Participants With Adverse Event Related to Injection Site Reactions

This is the number of participants with at least one clinically significant reaction at the injection site (e.g., erythema/redness, tenderness, swelling, induration, hemorrhage at the injection site) occurring on the days of intravenous (iv) selexipag injection.

Time frame:
From Day 2 to Day 3
Reported as:
Count of participants · Participants
Number of Participants With Adverse Event Related to Injection Site Reactions
ParticipantsSelexipag
Number of Participants With Adverse Event Related to Injection Site Reactions2
PrimaryNumber of Participants With Prostacyclin-associated AEs Leading to Study Treatment Discontinuation

This is the number of subjects who discontinued the i.v. selexipag treatment due to prostacyclin-associated adverse events (headache, diarrhea, nausea, vomiting, jaw pain, myalgia, pain in the extremity, flushing and arthralgia).

Time frame:
From Day 2 to Day 3
Reported as:
Count of participants · Participants
Number of Participants With Prostacyclin-associated AEs Leading to Study Treatment Discontinuation
ParticipantsSelexipag
Number of Participants With Prostacyclin-associated AEs Leading to Study Treatment Discontinuation0
PrimaryNumber of Participants With PAH-related Adverse Events

This is the number of participants with at least one AE considered to be related to pulmonary arterial hypertension during the course of the study.

Time frame:
From Day 1 to Day 37
Reported as:
Count of participants · Participants
Number of Participants With PAH-related Adverse Events
ParticipantsSelexipag
Number of Participants With PAH-related Adverse Events3

Adverse events

Collected over From Day 2 to Day 37. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selexipag0/20 (0%)2/20 (10%)13/20 (65%)
Most frequent serious events
Most frequent serious events
EventSelexipag
Right Ventricular FailureCardiac disorders1/20
Blindness UnilateralEye disorders1/20
Rhegmatogenous Retinal DetachmentEye disorders1/20
Most frequent other events
Showing 10 of 25
Most frequent other events
EventSelexipag
HeadacheNervous system disorders4/20
NauseaGastrointestinal disorders2/20
Infusion Site ErythemaGeneral disorders2/20
Oedema PeripheralGeneral disorders2/20
FlushingVascular disorders2/20
LymphadenopathyBlood and lymphatic system disorders1/20
TachycardiaCardiac disorders1/20
DiarrhoeaGastrointestinal disorders1/20
FlatulenceGastrointestinal disorders1/20
VomitingGastrointestinal disorders1/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Selexipag
Mean56.5 ± 9.43
Sex: Female, Male
Sex: Female, Male(Participants)Selexipag
Female16
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selexipag
Hispanic or Latino0
Not Hispanic or Latino20
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Selexipag
Asian1
Black or African American0
American Indian or Alaska Native0
Native Hawaiian or other Pacific Islander0
White19
Other0
Region of Enrollment
Region of Enrollment(Participants)Selexipag
Germany13
United States7
World Health Organization Functional classes (WHO FC)
World Health Organization Functional classes (WHO FC)(Participants)Selexipag
FC I1
FC II13
FC III6
Uptravi dose at screening
Uptravi dose at screening(Participants)Selexipag
200 ug twice daily0
400 ug twice daily1
600 ug twice daily2
800 ug twice daily2
1000 ug twice daily3
1200 ug twice daily2
1400 ug twice daily1
1600 ug twice daily9
PAH-specific therapies at baseline
PAH-specific therapies at baseline(Participants)Selexipag
PDE-5 inhibitors1
sGC stimulator1
ERA + PDE5-inhibitors13
ERA + sGC stimulator5

1 further baseline measures are reported on the registry.

08

Study locations

8 sites
  • University of California San Diego Medical center - PULM VASCULAR DIV
    La Jolla, California 92037, United States
  • TUFTS New England Medical Center - PULM / CRITICAL CARE & SLEEP
    Boston, Massachusetts 02111-1552, United States
  • Cleveland Clin Foundation - Dept of Pulm & Critical Care Med
    Cleveland, Ohio 44195, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-8550, United States
  • Universitätsklinikum Giessen und Marburg GmbH, Medizinische Klinik und Poliklinik II, Pneumologie
    Giessen, 35392, Germany
  • Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere Medizin B
    Greifswald, 17475, Germany
  • Universitätsklinikum Hamburg-Eppendorf, II. Medizinische Klinik und Poliklinik, Pneumologie
    Hamburg, 20246, Germany
  • Universitätsklinikum Leipzig / Medizinischen Klinik und Poliklinik I, Pneumologie
    Leipzig, 04103, Germany
09

References and documents

Publications

  • Klose H, Chin KM, Ewert R, Gall H, Parambil J, Poch D, Seyfarth HJ, Axelsen LN, Hsu Schmitz SF, Stein C, Preston IR. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study. Respir Res. 2021 Feb 3;22(1):34. doi: 10.1186/s12931-020-01594-8. PubMed 33536021 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in May 2018, 5 months.

Results were first posted in May 2019, 11 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 5 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2017
First posted
Jun 15, 2017
StartActual
Dec 4, 2017
Primary completionActual
May 29, 2018
CompletionActual
May 29, 2018
Results first posted
May 21, 2019
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03187678
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Jun 15, 2017
Start date
Dec 4, 2017
Primary completion
May 29, 2018
Completion
May 29, 2018
Results posted
May 21, 2019
Last update
Jun 29, 2025

Study contacts

Ralph Preiss
study director · Actelion

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion